Project Indication Platform
Pre-Clinical IND Enabling Phase I Phase II
SI-B001
EGFR×HER3
Solid tumor SEBA

80%

BL-B01D1
Bispecific
Solid tumor SHRI

45%

BL-M02D1
Monospecific
Lung cancer, TNBC SHRI

38%

BL-M07D1
Monospecific
BC, Gastric cancer SHRI

33%

SI-B003
CTLA-4×PD-1
Solid tumor SEBA

64%

GNC-038
CD3×41BB×PD-L1
×CD19
Lymphoma, leukemia, solid tumor GNC

61%

GNC-039
CD3×41BB×PD-L1
×EGFRvIII
Glioma, solid tumor GNC

58%

GNC-035
CD3×41BB×PD-L1
×ROR1
Lymphoma, leukemia, solid tumor GNC

50%

SI-F019
Bispecific ACE2
fusion protein
COVID-19, ARDS,
PAH
Fusion
Protein

70%


Targeted Therapy ADC Immunotherapy COVID